Two New Tests Introduced to Detect Alzheimer’s Biomarkers

Quanterix Corporation has commercially launched two novel phospho-tau assays: pTau 205 and pTau 212, expanding its portfolio of blood-based biomarkers for Alzheimer’s disease and neurodegeneration.

These new assays can precisely detect tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer’s disease. Developed on Quanterix’s ultra-sensitive Simoa platform, the pTau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers. 

Quanterix’s growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. 

“The addition of pTau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer’s,” Quanterix CEO Masoud Toloue, Ph.D., said. “Combined with the recent integration of Akoya’s spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we’re advancing the future of precision diagnostics across neurology, oncology, and immunology.” 

The newly launched p-Tau 205 and p-Tau 212 assays are now available for use on the HD-X or SR-X instruments or testing directly through Quanterix’s in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia. 

Quanterix provides ultra-sensitive biomarker detection solutions, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa technology delivers sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a partner to the scientific community for nearly two decades. This year, Quanterix acquired Akoya Biosciences, The Spatial Biology Company, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers an integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics.